Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Diabetes Mellitus HELP
Based on 100,000 articles published since 2008
|||| 37 

These are the 100000 published articles about Diabetes Mellitus that originated from Worldwide during 2008-2018.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Insulin Access and Affordability Working Group: Conclusions and Recommendations. 2018

Cefalu, William T / Dawes, Daniel E / Gavlak, Gina / Goldman, Dana / Herman, William H / Van Nuys, Karen / Powers, Alvin C / Taylor, Simeon I / Yatvin, Alan L / Anonymous2741233. ·American Diabetes Association, Arlington, VA wcefalu@diabetes.org. · Morehouse School of Medicine, Atlanta, GA. · North Coast Health, Lakewood, OH. · USC Schaeffer Center for Health Policy & Economics, Los Angeles, CA. · University of Michigan, Ann Arbor, MI. · Vanderbilt University Medical Center, Nashville, TN. · University of Maryland School of Medicine, Baltimore, MD. · Popper & Yatvin, Philadelphia, PA. ·Diabetes Care · Pubmed #29739814.

ABSTRACT: -- No abstract --

2 Guideline The Berlin Declaration: A call to action to improve early actions related to type 2 diabetes. How can specialist care help? 2018

Ceriello, Antonio / Gavin, James R / Boulton, Andrew J M / Blickstead, Rick / McGill, Margaret / Raz, Itamar / Sadikot, Shaukat / Wood, David A / Cos, Xavier / Khunti, Kamlesh / Kalra, Sanjay / Das, Ashok Kumar / López, Cutberto Espinosa / Anonymous5301165. ·Department of Cardiovascular and Metabolic Diseases, IRCCS Multimedica, Milan, Italy; Insititut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain. Electronic address: aceriell@clinic.ub.es. · Emory University School of Medicine, Atlanta, GA, USA. · Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. · Diabetes Canada, Toronto, Canada. · Central Clinical School, The University of Sydney, Sydney, Australia; The Diabetes Centre, Royal Prince Alfred Hospital, Sydney, Australia. · Hadassah Ein Kerem Hospital, Jerusalem, Israel. · Department of Endocrinology/Diabetology, Jaslok Hospital and Research Centre, Mumbai, India. · International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, UK. · Sant Marti de Provençals Primary Care Centres, Institut Català de la Salut, Barcelona, Spain; University Research Institute in Primary Care (IDIAP Jordi Gol), Barcelona, Spain. · Diabetes Research Centre, University of Leicester, Leicester, United Kingdom. · Bharti Hospital and B.R.I.D.E., Karnal, India. · Pondicherry Institute of Medical Sciences, Pondicherry, Puducherry, India. · CENAPRECE "National Center for Preventive Programs and Disease Control", Mexico City, Mexico. ·Diabetes Res Clin Pract · Pubmed #29596943.

ABSTRACT: Diabetes is a major global epidemic and places a huge burden on healthcare systems worldwide. The complications of type 2 diabetes (T2D) and related hospitalizations are major contributors to this burden, and there is strong evidence that the risk for these can be reduced by early action to identify and prevent progression of people at high risk of T2D and ensure tight glycemic control in those with established disease. In response to this, the Berlin Declaration was developed by four working groups of experts and ratified by healthcare professionals from 38 countries. Its aim is to act as a global call to action for early intervention in diabetes, in addition to providing short-, medium- and long-term targets that should be relevant to all nations. The Berlin Declaration focuses on four aspects of early action, and proposes actionable policies relating to each aspect: early detection, prevention, early control and early access to the right interventions. In addition, a number of treatment targets are proposed to provide goals for these policies. To ensure that the suggested policies are enacted in the most effective manner, the support of specialist care professionals is considered essential.

3 Guideline AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY 2018 POSITION STATEMENT ON INTEGRATION OF INSULIN PUMPS AND CONTINUOUS GLUCOSE MONITORING IN PATIENTS WITH DIABETES MELLITUS. 2018

Grunberger, George / Handelsman, Yehuda / Bloomgarden, Zachary T / Fonseca, Vivian A / Garber, Alan J / Haas, Richard A / Roberts, Victor L / Umpierrez, Guillermo E. · ·Endocr Pract · Pubmed #29547046.

ABSTRACT: This document represents the official position of the American Association of Clinical Endocrinologists and American College of Endocrinology. Where there are no randomized controlled trials or specific U.S. FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience. Every effort was made to achieve consensus among the committee members. Position statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician. AACE/ACE Task Force on Integration of Insulin Pumps and Continuous Glucose Monitoring in the Management of Patients With Diabetes Mellitus Chair George Grunberger, MD, FACP, FACE Task Force Members Yehuda Handelsman, MD, FACP, FNLA, MACE Zachary T. Bloomgarden, MD, MACE Vivian A. Fonseca, MD, FACE Alan J. Garber, MD, PhD, FACE Richard A. Haas, MD, FACE Victor L. Roberts, MD, MBA, FACP, FACE Guillermo E. Umpierrez, MD, CDE, FACP, FACE Abbreviations: AACE = American Association of Clinical Endocrinologists ACE = American College of Endocrinology A1C = glycated hemoglobin BGM = blood glucose monitoring CGM = continuous glucose monitoring CSII = continuous subcutaneous insulin infusion DM = diabetes mellitus FDA = Food & Drug Administration MDI = multiple daily injections T1DM = type 1 diabetes mellitus T2DM = type 2 diabetes mellitus SAP = sensor-augmented pump SMBG = self-monitoring of blood glucose STAR 3 = Sensor-Augmented Pump Therapy for A1C Reduction phase 3 trial.

4 Guideline Claimed effects, outcome variables and methods of measurement for health claims proposed under European Community Regulation 1924/2006 in the area of blood glucose and insulin concentrations. 2018

Martini, Daniela / Biasini, Beatrice / Zavaroni, Ivana / Bedogni, Giorgio / Musci, Marilena / Pruneti, Carlo / Passeri, Giovanni / Ventura, Marco / Galli, Daniela / Mirandola, Prisco / Vitale, Marco / Dei Cas, Alessandra / Bonadonna, Riccardo C / Del Rio, Daniele. ·The Laboratory of Phytochemicals in Physiology, Department of Food and Drug, University of Parma, Medical School, Building A, Via Volturno 39, 43125, Parma, Italy. · The Laboratory of Phytochemicals in Physiology, Department of Food Science, University of Parma, Medical School, Building A, Via Volturno 39, 43125, Parma, Italy. · Division of Endocrinology, Department of Medicine and Surgery, University of Parma, Parma, Italy. · Azienda Ospedaliera Universitaria of Parma, Parma, Italy. · Clinical Epidemiology Unit, Liver Research Center, Basovizza, Trieste, Italy. · Department of Food and Drug, University of Parma, Parma, Italy. · Department of Medicine and Surgery, Clinical Psychology Unit, University of Parma, Medical School Building, Parma, Italy. · Department of Medicine and Surgery, Building Clinica Medica Generale, University of Parma, Parma, Italy. · Laboratory of Probiogenomics, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy. · Department of Medicine and Surgery, Sport and Exercise Medicine Centre (SEM), University of Parma, Parma, Italy. · The Laboratory of Phytochemicals in Physiology, Department of Food and Drug, University of Parma, Medical School, Building A, Via Volturno 39, 43125, Parma, Italy. daniele.delrio@unipr.it. ·Acta Diabetol · Pubmed #29383587.

ABSTRACT: Most requests for authorization to bear health claims under Articles 13(5) and 14 related to blood glucose and insulin concentration/regulation presented to the European Food Safety Authority (EFSA) receive a negative opinion. Reasons for such decisions are mainly ascribable to poor substantiation of the claimed effects. In this scenario, a project was carried out aiming at critically analysing the outcome variables (OVs) and methods of measurement (MMs) to be used to substantiate health claims, with the final purpose to improve the quality of applications provided by stakeholders to EFSA. This manuscript provides a position statement of the experts involved in the project, reporting the results of an investigation aimed to collect, collate and critically analyse the information relevant to claimed effects (CEs), OVs and MMs related to blood glucose and insulin levels and homoeostasis compliant with Regulation 1924/2006. The critical analysis of OVs and MMs was performed with the aid of the pertinent scientific literature and was aimed at defining their appropriateness (alone or in combination with others) to support a specific CE. The results can be used to properly select OVs and MMs in a randomized controlled trial, for an effective substantiation of the claims, using the reference method(s) whenever available. Moreover, results can help EFSA in updating the guidance for the scientific requirements of health claims.

5 Guideline AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON TESTING FOR AUTONOMIC AND SOMATIC NERVE DYSFUNCTION. 2017

Vinik, Aaron I / Camacho, Pauline M / Davidson, Jaime A / Handelsman, Yehuda / Lando, Howard M / Leddy, Anne L / Reddy, Sethu K / Cook, Richard / Spallone, Vicenza / Tesfaye, Solomon / Ziegler, Dan / Anonymous2521077. · ·Endocr Pract · Pubmed #29320641.

ABSTRACT: This document represents the official position of the American Association of Clinical Endocrinologists and the American College of Endocrinology. Where there were no randomized controlled trials or specific U.S. FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience. Every effort was made to achieve consensus among the committee members. Position statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician.

6 Guideline [Recommendations for the use of ranibizumab in diabetic macular edema at IMSS]. 2017

Ortiz-Lerma, Roberto / González-Cervantes, Carlos Pedro / Hernández-Núñez, Fabiola / Ancona-Durán, Irene / Betesh-Rodríguez, Isaac / Méndez, Noé / Garza-Cantú, Daniel / López-Martínez, Óscar / Martínez-Ruiz, Adriana Marcela / López-Montero, Luis Miguel / Muñoz, Armando / Blancas-Ontiveros, Jorge Alberto / Fernández-Trejo, Carlos Mariano / Mayorga-Rubalcava, Juan Carlos / Flores-Góngora, Silvia Elizabeth / Gómez-Galván, Jorge Luis / Domínguez-Álvarez, Patricia Armida / Sánchez-Hernández, Erik / Cantú-Yeverinon, Homero. ·aJefatura del Servicio de Oftalmología, Hospital General "Dr. Gaudencio González Garza", Centro Médico Nacional La Raza, Ciudad de México. ·Rev Med Inst Mex Seguro Soc · Pubmed #29190870.

ABSTRACT: Diabetic macular edema can occur at any stage of diabetic retinopathy. It represents the main cause of vision loss in diabetes type I and II with a prevalence of 3-10% in diabetic patients of the Instituto Mexicano del Seguro Social (IMSS). Our aim is to elaborate treatment guidelines and provide recommendations for the use of intravitreal ranibizumab for diabetic medical edema at IMSS. Nine retina specialists and 10 ophthalmologists from IMSS high specialty medical units gathered to discuss the bibliographic evidence for the safety and efficacy of ranibizumab for this disease, in order to create consensus on its use in the institution. Intravitreal ranibizumab injection should be used on patients presenting diffuse or cystic diabetic macular edema who have strict metabolic control and visual acuity between 20/30 and 20/200 ETDRS, as well as structural features, such as inferior foveal limit of 280 μm and ischemic areas no larger than 50% of the central foveal area. Treatment regime should consist of a loading charge of three monthly injections of ranibizumab 0.5 mg, followed by monthly follow-ups and treatment as needed according to anatomic and functional criteria. This consensus decision-making process on the criteria to treat and re-treat patients with this drug will result in better health outcomes than those currently observed among patients with diabetic macular edema at IMSS.

7 Guideline Excerpt from the Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy. 2017

Hooper, Philip / Boucher, Marie Carole / Cruess, Alan / Dawson, Keith G / Delpero, Walter / Greve, Mark / Kozousek, Vladimir / Lam, Wai-Ching / Maberley, David A L. ·Philip Hooper, London, ON (Chair) (retina and uveitis); Marie Carole Boucher, Montreal, QC (retina and teleophthalmology); Alan Cruess, Halifax, NS (retina); Keith G. Dawson, Vancouver, BC (endocrinology); Walter Delpero, Ottawa, ON (cataract and strabismus); Mark Greve, Edmonton, AB (retina and teleophthalmology); Vladimir Kozousek, Halifax, NS (medical retina); Wai-Ching Lam, Toronto, ON (retina and research); David A.L. Maberley, Vancouver, BC (retina).. Electronic address: cjo@cos-sco.ca. · Philip Hooper, London, ON (Chair) (retina and uveitis); Marie Carole Boucher, Montreal, QC (retina and teleophthalmology); Alan Cruess, Halifax, NS (retina); Keith G. Dawson, Vancouver, BC (endocrinology); Walter Delpero, Ottawa, ON (cataract and strabismus); Mark Greve, Edmonton, AB (retina and teleophthalmology); Vladimir Kozousek, Halifax, NS (medical retina); Wai-Ching Lam, Toronto, ON (retina and research); David A.L. Maberley, Vancouver, BC (retina). ·Can J Ophthalmol · Pubmed #29074014.

ABSTRACT: -- No abstract --

8 Guideline Synopsis of the 2017 U.S. Department of Veterans Affairs/U.S. Department of Defense Clinical Practice Guideline: Management of Type 2 Diabetes Mellitus. 2017

Conlin, Paul R / Colburn, Jeffrey / Aron, David / Pries, Rose Mary / Tschanz, Mark P / Pogach, Leonard. ·From VA Boston Healthcare System, West Roxbury, Massachusetts; San Antonio Military Medical Center, Fort Sam Houston, Texas; Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio; VHA National Center for Health Promotion and Disease Prevention, Durham, North Carolina; San Diego Internal Medicine, San Diego, California; and Veterans Affairs Central Office, Office of Specialty Care Services, Washington, DC. ·Ann Intern Med · Pubmed #29059687.

ABSTRACT: Description: In April 2017, the U.S. Department of Veterans Affairs (VA) and the U.S. Department of Defense (DoD) approved a joint clinical practice guideline for the management of type 2 diabetes mellitus. Methods: The VA/DoD Evidence-Based Practice Work Group convened a joint VA/DoD guideline development effort that included a multidisciplinary panel of practicing clinician stakeholders and conformed to the Institute of Medicine's tenets for trustworthy clinical practice guidelines. The guideline panel developed key questions in collaboration with the ECRI Institute, which systematically searched and evaluated the literature through June 2016, developed an algorithm, and rated recommendations by using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Recommendations: This synopsis summarizes key features of the guideline in 7 areas: patient-centered care and shared decision making, glycemic biomarkers, hemoglobin A1c target ranges, individualized treatment plans, outpatient pharmacologic treatment, glucose targets for critically ill patients, and treatment of hospitalized patients.

9 Guideline Insulin therapy for adult patients with type 2 diabetes mellitus: a position statement of the Korean Diabetes Association, 2017. 2017

Lee, Byung-Wan / Kim, Jin Hwa / Ko, Seung-Hyun / Hur, Kyu Yeon / Kim, Nan-Hee / Rhee, Sang Youl / Kim, Hyun Jin / Moon, Min Kyong / Park, Seok-O / Choi, Kyung Mook / Anonymous4461194. ·Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. · Division of Endocrinology and Metabolism, Department of Internal Medicine, Chosun University College of Medicine, Gwangju, Korea. · Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. · Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. · Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. · Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea. · Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea. · Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea. · Department of Internal Medicine, Gwangmyeong Sungae Hospital, Gwangmyeong, Korea. ·Korean J Intern Med · Pubmed #29057642.

ABSTRACT: The Korean Diabetes Association (KDA) has regularly updated its Clinical Practice Guidelines. In 2017, the KDA published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). Growing evidence from new multinational clinical trials using novel and traditional insulin analogues has also been accumulated. Following global trends, many results of clinical trials, especially concerning the clinical efficacy and safety of insulin therapy, have been published about Korean patients with T2DM. After a systematic search of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the initiation, choice, and intensification of insulin and created an insulin treatment algorithm for the first time to guide physicians caring for adult Korean patients with T2DM.

10 Guideline Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association. 2017

Ko, Seung-Hyun / Hur, Kyu Yeon / Rhee, Sang Youl / Kim, Nan-Hee / Moon, Min Kyong / Park, Seok-O / Lee, Byung-Wan / Kim, Hyun Jin / Choi, Kyung Mook / Kim, Jin Hwa / Anonymous4451194. ·Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. · Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. · Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea. · Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. · Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea. · Department of Internal Medicine, Gwangmyeong Sungae Hospital, Gwangmyeong, Korea. · Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. · Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea. · Division of Endocrinology and Metabolism, Department of Internal Medicine, Chosun University College of Medicine, Gwangju, Korea. ·Korean J Intern Med · Pubmed #29056038.

ABSTRACT: In 2017, the Korean Diabetes Association (KDA) published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). The KDA regularly updates its Clinical Practice Guidelines, but since the last update in 2015, many results from clinical trials have been introduced, and domestic data from studies performed in Korean patients with T2DM have been published. Recently, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations. Additionally, new data from clinical trials using dipeptidyl peptidase 4 inhibitors and thiazolidinediones in Korean patients with T2DM were added. Following a systematic review and assessment of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the use of antihyperglycemic agents and revised the treatment algorithm for Korean adult patients with T2DM.

11 Guideline Management della retinopatia diabetica e dell'edema maculare diabetico: linee guida "Euretina 2017". 2017

Turchetti, P / Librando, A / Angelucci, F / Carlesimo, S C / Migliorini, R. ·Istituto Nazionale per la promozione della salute delle popolazioni Migranti ed il contrasto delle malattie della Povertà. (INMP/NIHMP), Rome 00153, Italia. · Dipartimento Organi di Senso, Facoltà di Medicina e Odontoiatria, Sapienza Università di Roma, Italia. · Centro specialistico di Salute Aurelia S.R.L., Roma, Italia. ·Clin Ter · Pubmed #29044359.

ABSTRACT: Si prevede che la malattia diabetica con tutte le sue complicanze avrà un forte aumento di incidenza con un grosso impatto socioeconomico nei prossimi decenni in tutto il mondo. Pertanto ben si comprende l'importanza di individuare attraverso una fine diagnostica quanto più precocemente la comparsa dei sintomi diabetici, migliorare lo stile di vita ed impostare cure efficienti. Riportiamo la serie di raccomandazioni EURETINA 2017, dei maggiori esperti in Europa per la gestione della malattia diabetica e delle complicanze della retina. Per combattere questa "pestilenza" occorre un team medico preparato. Il trattamento laser è stato considerato sino a non molto tempo fa il Gold standard della retinopatia diabetica e dell'edema diabetico (RD e EMD). Recenti studi hanno dimostrato, invece, che si possono raggiungere risultati migliori mediante l'iniezione diretta di farmaci nella cavità vitreale. In particolare è emerso terapia di prima linea, molecole in grado di inibire il fattore di crescita endoteliale vascolare (anti VEGF) mentre non è più raccomandata la fotocoagulazione laser per il trattamento del DME. Nell'ambito delle molecole farmacologiche gli steroidi hanno mantenuto un ruolo nella gestione del DME cronicamente persistente.

12 Guideline Diabetes in older people: position statement of The Hong Kong Geriatrics Society and the Hong Kong Society of Endocrinology, Metabolism and Reproduction. 2017

Wong, C W / Lee, J Sw / Tam, K F / Hung, H F / So, W Y / Shum, C K / Lam, C Y / Cheng, J N / Man, S P / Auyeung, T W. ·Department of Medicine and Geriatrics, Caritas Medical Centre, Sham Shui Po, Hong Kong. · Department of Medicine and Geriatrics, Tai Po Hospital, Tai Po, Hong Kong. · Department of Medicine, Hong Kong Buddhist Hospital, Lok Fu, Hong Kong. · Department of Medicine and Geriatrics, Princess Margaret Hospital, Lai Chi Kok, Hong Kong. · Department of Medicine and Therapeutics, Prince of Wales Hospital, Shatin, Hong Kong. · Department of Medicine and Geriatrics, Tuen Mun Hospital, Tuen Mun, Hong Kong. · Department of Medicine, Queen Elizabeth Hospital, Jordan, Hong Kong. · Department of Medicine and Geriatrics, Pok Oi Hospital, Yuen Long, Hong Kong. ·Hong Kong Med J · Pubmed #29026049.

ABSTRACT: Following a survey on the clinical practice of geriatricians in the management of older people with diabetes and a study of hypoglycaemia in diabetic patients, a round-table discussion with geriatricians and endocrinologists was held in January 2015. Consensus was reached for six domains specifically related to older diabetic people: (1) the considerations when setting an individualised diabetic management; (2) inclusion of geriatric syndrome screening in assessment; (3) glycaemic and blood pressure targets; (4) pharmacotherapy; (5) restrictive diabetic diet; and (6) management goals for nursing home residents.

13 Guideline Treatment of Type 1 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes. 2017

Chamberlain, James J / Kalyani, Rita Rastogi / Leal, Sandra / Rhinehart, Andrew S / Shubrook, Jay H / Skolnik, Neil / Herman, William H. ·From St. Mark's Hospital and St. Mark's Diabetes Center, Salt Lake City, Utah; Johns Hopkins University, Baltimore, Maryland; SinfoníaRx, Tucson, Arizona; Glytec, Marco Island, Florida; Touro University College of Osteopathic Medicine, Vallejo, California; Abington Memorial Hospital, Jenkintown, Pennsylvania; and University of Michigan, Ann Arbor, Michigan. ·Ann Intern Med · Pubmed #28892816.

ABSTRACT: Description: The American Diabetes Association (ADA) annually updates Standards of Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of patients with diabetes. Methods: For the 2017 Standards of Care, the ADA Professional Practice Committee did MEDLINE searches from 1 January 2016 to November 2016 to add, clarify, or revise recommendations on the basis of new evidence. The committee rated the recommendations as A, B, or C, depending on the quality of evidence, or E for expert consensus or clinical experience. The Standards of Care were reviewed and approved by the Executive Committee of the ADA Board of Directors, which includes health care professionals, scientists, and laypersons. Feedback from the larger clinical community informed revisions. Recommendation: This synopsis focuses on recommendations from the 2017 Standards of Care about monitoring and pharmacologic approaches to glycemic management for type 1 diabetes.

14 Guideline ISPAD Guidelines. Managing diabetes in preschool children. 2017

Sundberg, Frida / Barnard, Katharine / Cato, Allison / de Beaufort, Carine / DiMeglio, Linda A / Dooley, Greg / Hershey, Tamara / Hitchcock, Jeff / Jain, Vandana / Weissberg-Benchell, Jill / Rami-Merhar, Birgit / Smart, Carmel E / Hanas, Ragnar. ·The Queen Silvia Children's Hospital, Sahlgrenska University Hospital, Gothenburg, Sweden. · Institute of Clinical Sciences, Department of Pediatrics, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden. · Faculty of Health and Social Sciences, Bournemouth University, Bournemouth, UK. · Neurology Division, Nemours Children's Health System, Jacksonville, Florida. · Clinique Pediatrique, Centre Hospitalier de Luxembourg (CHL), Luxembourg, Luxembourg. · Department of Pediatrics, UZ Brussels, Jette, Belgium. · Department of Pediatrics, Section of Pediatric Endocrinology/Diabetology, Indiana University School of Medicine, Indianapolis, Indiana. · inspiredbyisabella.com. · Psychiatry Department, Washington University School of Medicine, St. Louis, Missouri. · Radiology Department, Washington University School of Medicine, St. Louis, Missouri. · childrenwithdiabetes.com. · Pediatric Endocrinology Division, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India. · Northwestern University Feinberg School of Medicine, Chicago, Illinois. · Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois. · Department of Pediatric and Adolescent Medicine, Medical University of Vienna, Vienna, Austria. · Department of Endocrinology, John Hunter Children's Hospital and University of Newcastle, Newcastle, Australia. · Department of Pediatrics, NU Hospital Group, Uddevalla, Sweden. ·Pediatr Diabetes · Pubmed #28726299.

ABSTRACT: -- No abstract --

15 Guideline [2016 European guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts. Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation]. 2017

Piepoli, Massimo F / Hoes, Arno W / Agewall, Stefan / Albus, Christian / Brotons, Carlos / Catapano, Alberico L / Cooney, Marie-Therese / Corrà, Ugo / Cosyns, Bernard / Deaton, Christi / Graham, Ian / Hall, Michael Stephen / Hobbs, F D Richard / Løchen, Maja-Lisa / Löllgen, Herbert / Marques-Vidal, Pedro / Perk, Joep / Prescott, Eva / Redon, Josep / Richter, Dimitrios J / Sattar, Naveed / Smulders, Yvo / Tiberi, Monica / van der Worp, H Bart / van Dis, Ineke / Verschuren, W M Monique. ·European Society of Cardiology (ESC). · International Society of Behavioural Medicine (ISBM). · WONCA Europe. · European Atherosclerosis Society (EAS). · International Diabetes Federation European Region (IDF Europe). · International Federation of Sport Medicine (FIMS). · European Society of Hypertension (ESH). · European Association for the Study of Diabetes (EASD). · European Stroke Organisation (ESO). · European Heart Network (EHN). ·G Ital Cardiol (Rome) · Pubmed #28714997.

ABSTRACT: -- No abstract --

16 Guideline Polish Forum for Prevention Guidelines on Diabetes: update 2017. 2017

Małecki, Maciej / Kozek, Elżbieta / Zozulińska-Ziółkiewicz, Dorota / Kopeć, Grzegorz / Knap, Klaudia / Sarnecka, Agnieszka / Podolec, Jakub / Pająk, Andrzej / Zdrojewski, Tomasz / Czarnecka, Danuta / Jankowski, Piotr / Nowicka, Grażyna / Windak, Adam / Stańczyk, Jerzy / Undas, Anetta / Członkowska, Anna / Niewada, Maciej / Podolec, Piotr. ·Department of Cardiac and Vascular Diseases, Institute of Cardiology, Jagiellonian University Medical College at John Paul II Hospital, Kraków. ppodolec@interia.pl. ·Kardiol Pol · Pubmed #28707289.

ABSTRACT: -- No abstract --

17 Guideline AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE. 2017

Cobin, Rhoda H / Goodman, Neil F / Anonymous2741041. · ·Endocr Pract · Pubmed #28703650.

ABSTRACT: EXECUTIVE SUMMARY This American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE) Position Statement is designed to update the previous menopause clinical practice guidelines published in 2011 but does not replace them. The current document reviews new clinical trials published since then as well as new information regarding possible risks and benefits of therapies available for the treatment of menopausal symptoms. AACE reinforces the recommendations made in its previous guidelines and provides additional recommendations on the basis of new data. A summary regarding this position statement is listed below: New information available from randomized clinical trials and epidemiologic studies reported after 2011 was critically reviewed. No previous recommendations from the 2011 menopause clinical practice guidelines have been reversed or changed. Newer information enhances AACE's guidance for the use of hormone therapy in different subsets of women. Newer information helps to support the use of various types of estrogens, selective estrogen-receptor modulators (SERMs), and progesterone, as well as the route of delivery. Newer information supports the previous recommendation against the use of bioidentical hormones. The use of nonhormonal therapies for the symptomatic relief of menopausal symptoms is supported. Newer information enhances AACE's guidance for the use of hormone therapy in different subsets of women. Newer information helps to support the use of various types of estrogens, SERMs, and progesterone, as well as the route of delivery. Newer information supports the previous recommendation against the use of bioidentical hormones. The use of nonhormonal therapies for the symptomatic relief of menopausal symptoms is supported. New recommendations in this position statement include: 1. RECOMMENDATION: the use of menopausal hormone therapy in symptomatic postmenopausal women should be based on consideration of all risk factors for cardiovascular disease, age, and time from menopause. 2. RECOMMENDATION: the use of transdermal as compared with oral estrogen preparations may be considered less likely to produce thrombotic risk and perhaps the risk of stroke and coronary artery disease. 3. RECOMMENDATION: when the use of progesterone is necessary, micronized progesterone is considered the safer alternative. 4. RECOMMENDATION: in symptomatic menopausal women who are at significant risk from the use of hormone replacement therapy, the use of selective serotonin re-uptake inhibitors and possibly other nonhormonal agents may offer significant symptom relief. 5. RECOMMENDATION: AACE does not recommend use of bioidentical hormone therapy. 6. RECOMMENDATION: AACE fully supports the recommendations of the Comité de l'Évolution des Pratiques en Oncologie regarding the management of menopause in women with breast cancer. 7. RECOMMENDATION: HRT is not recommended for the prevention of diabetes. 8. RECOMMENDATION: In women with previously diagnosed diabetes, the use of HRT should be individualized, taking in to account age, metabolic, and cardiovascular risk factors. ABBREVIATIONS: AACE = American Association of Clinical Endocrinologists; ACE = American College of Endocrinology; BMI = body mass index; CAC = coronary artery calcification; CEE = conjugated equine estrogen; CEPO = Comité de l'Évolution des Pratiques en Oncologie; CAD = coronary artery disease; CIMT = carotid intima media thickness; CVD = cardiovascular disease; FDA = Food and Drug Administration; HDL = high-density lipoprotein; HRT = hormone replacement therapy; HT = hypertension; KEEPS = Kronos Early Estrogen Prevention Study; LDL = low-density lipoprotein; MBS = metabolic syndrome; MPA = medroxyprogesterone acetate; RR = relative risk; SERM = selective estrogen-receptor modulator; SSRI = selective serotonin re-uptake inhibitor; VTE = venous thrombo-embolism; WHI = Women's Health Initiative.

18 Guideline A Practical Guide to the Use of Glucose-Lowering Agents With Cardiovascular Benefit or Proven Safety. 2017

Fitchett, David / Cheng, Alice / Connelly, Kim / Goldenberg, Ronald / Goodman, Shaun G / Leiter, Lawrence A / Lonn, Eva / Paty, Breay / Poirier, Paul / Stone, James / Thompson, David / Yale, Jean-Francois / Mancini, G B John. ·Division of Cardiology, St Michael's Hospital, Li Ka Shing Knowledge Institute and Keenan Research Centre for Biomedical Science, University of Toronto, Toronto, Ontario, Canada. Electronic address: fitchettd@smh.ca. · Division of Endocrinology and Metabolism, University of Toronto, Toronto, Ontario, Canada. · Division of Cardiology, St Michael's Hospital, Li Ka Shing Knowledge Institute and Keenan Research Centre for Biomedical Science, University of Toronto, Toronto, Ontario, Canada. · Endocrinology and Metabolism, North York General Hospital and LMC Diabetes and Endocrinology, Toronto, Ontario, Canada. · Division of Endocrinology and Metabolism, Li Ka Shing Knowledge Institute and Keenan Research Centre for Biomedical Science, University of Toronto, Toronto, Ontario, Canada. · Population Health Research Institute and Department of Medicine, McMaster University, Hamilton, Ontario, Canada. · Division of Endocrinology, University of British Columbia, Vancouver, British Columbia, Canada. · Heart and Lung Institute, Laval University, Québec City, Québec, Canada. · Department of Cardiac Sciences, Libin Cardiovascular Institute of Alberta, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. · Division of Endocrinology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada. · Division of Endocrinology, McGill University Health Centre, McGill University, Montreal, Canada. ·Can J Cardiol · Pubmed #28668144.

ABSTRACT: Patients with type 2 diabetes continue to have a high residual risk for cardiovascular events despite intensive risk factor modification. Recent clinical trials have shown that the antihyperglycemic agents empagliflozin and liraglutide reduce cardiovascular events. Other drugs have been shown to have cardiovascular safety. With glucose-lowering agents proven to reduce adverse cardiovascular outcomes, many cardiologists have begun to prescribe or recommend glucose-lowering agents. Other cardiologists are not yet comfortable with this role because they are not accustomed to initiating these drugs. This document provides updated details of glucose-lowering agents associated with either proven cardiovascular benefit or safety, to help cardiologists to safely prescribe and monitor their patients with diabetes.

19 Guideline Practice Bulletin No. 180: Gestational Diabetes Mellitus. 2017

Anonymous2461093. · ·Obstet Gynecol · Pubmed #28644336.

ABSTRACT: Gestational diabetes mellitus (GDM) is one of the most common medical complications of pregnancy. However, debate continues to surround the diagnosis and treatment of GDM despite several recent large-scale studies addressing these issues. The purposes of this document are the following: 1) provide a brief overview of the understanding of GDM, 2) review management guidelines that have been validated by appropriately conducted clinical research, and 3) identify gaps in current knowledge toward which future research can be directed.

20 Guideline Practice Bulletin No. 180 Summary: Gestational Diabetes Mellitus. 2017

Anonymous301200. · ·Obstet Gynecol · Pubmed #28644329.

ABSTRACT: GESTATIONAL DIABETES MELLITUS: Gestational diabetes mellitus (GDM) is one of the most common medical complications of pregnancy. However, debate continues to surround the diagnosis and treatment of GDM despite several recent large-scale studies addressing these issues. The purposes of this document are the following: 1) provide a brief overview of the understanding of GDM, 2) review management guidelines that have been validated by appropriately conducted clinical research, and 3) identify gaps in current knowledge toward which future research can be directed.

21 Guideline Polish Gynecological Society Recommendations for Labor Induction. 2017

Bomba-Opoń, Dorota / Drews, Krzysztof / Huras, Hubert / Laudański, Piotr / Paszkowski, Tomasz / Wielgoś, Mirosław. ·miroslaw.wielgos@wum.edu.pl. ·Ginekol Pol · Pubmed #28509326.

ABSTRACT: Labor induction involves artificial stimulation of childbirth before the natural, spontaneous onset of labor. It is one of the most common procedures in modern obstetrics. The frequency of labor induction has doubled in recent decades due to the development of perinatology and methods of monitoring fetal well-being in particular. Currently, one in five pregnant women and 30-40% of women delivering vaginally undergo this procedure. Reasons for induction include reduction of the perinatal mortality and morbidity of the fetus and newborn, as well as the reduction of maternal complications. However, as every medical intervention, labor induction is associated with a risk of complications.

22 Guideline Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease. 2017

Gale, R / Scanlon, P H / Evans, M / Ghanchi, F / Yang, Y / Silvestri, G / Freeman, M / Maisey, A / Napier, J. ·The Action on DMO group, UK. · The York Hospital, York, UK. · Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, UK. · University Hospital, Llandough, Cardiff, UK. · Bradford Teaching Hospitals, Bradford, UK. · The Royal Wolverhampton NHS Trust, Wolverhampton, UK. · Belfast Health & Social Care Trust, Belfast, UK. · Royal Hallamshire Hospital, Sheffield, UK. · Cardiff and Vale University Health Board, University Hospital of Wales, Cardiff, UK. · Bayer, Reading, UK. ·Eye (Lond) · Pubmed #28490797.

ABSTRACT: This paper identifies best practice recommendations for managing diabetes and sight-threatening diabetic eye disease. The authors provide an update for ophthalmologists and allied healthcare professionals on key aspects of diabetes management, supported by a review of the pertinent literature, and recommend practice principles for optimal patient management in treating visual impairment due to diabetic eye disease. In people with diabetes, early optimal glycaemic control reduces the long-term risk of both microvascular and macrovascular complications. The authors propose more can and should be done to maximise metabolic control, promote appropriate behavioural modifications and encourage timely treatment intensification when indicated to ameliorate diabetes-related complications. All people with diabetes should be screened for sight-threatening diabetic retinopathy promptly and regularly. It is shown that attitudes towards treatment adherence in diabetic macular oedema appear to mirror patients' views and health behaviours towards the management of their own diabetes. Awareness of diabetic macular oedema remains low among people with diabetes, who need access to education early in their disease about how to manage their diabetes to delay progression and possibly avoid eye-related complications. Ophthalmologists and allied healthcare professionals play a vital role in multidisciplinary diabetes management and establishment of dedicated diabetic macular oedema clinics is proposed. A broader understanding of the role of the diabetes specialist nurse may strengthen the case for comprehensive integrated care in ophthalmic practice. The recommendations are based on round table presentations and discussions held in London, UK, September 2016.

23 Guideline Vitamin D supplementation in the prevention and management of major chronic diseases not related to mineral homeostasis in adults: research for evidence and a scientific statement from the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO). 2017

Cianferotti, Luisella / Bertoldo, Francesco / Bischoff-Ferrari, Heike A / Bruyere, Olivier / Cooper, Cyrus / Cutolo, Maurizio / Kanis, John A / Kaufman, Jean-Marc / Reginster, Jean-Yves / Rizzoli, Rene / Brandi, Maria Luisa. ·Bone Metabolic Diseases Unit, Department of Surgery and Translational Medicine, University Hospital of Florence and University of Florence, Florence, Italy. · Department of Medicine, University of Verona, Verona, Italy. · Department of Geriatrics and Aging Research, University Hospital Zurich and University of Zurich, Zurich, Switzerland. · Epidemiology and Public Health, University of Liege, CHU Sart Tilman, Liege, 4000, Belgium. · MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, Hants, UK. · Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy. · Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK. · Institute for Health and Aging, Catholic University of Australia, Melbourne, VIC, Australia. · Department of Endocrinology and Unit for Osteoporosis and Metabolic Bone Diseases, Ghent University Hospital, Ghent, Belgium. · Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium. · Service of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland. · Bone Metabolic Diseases Unit, Department of Surgery and Translational Medicine, University Hospital of Florence and University of Florence, Florence, Italy. marialuisa.brandi@unifi.it. ·Endocrine · Pubmed #28390010.

ABSTRACT: INTRODUCTION: Optimal vitamin D status promotes skeletal health and is recommended with specific treatment in individuals at high risk for fragility fractures. A growing body of literature has provided indirect and some direct evidence for possible extraskeletal vitamin D-related effects. PURPOSE AND METHODS: Members of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis have reviewed the main evidence for possible proven benefits of vitamin D supplementation in adults at risk of or with overt chronic extra-skeletal diseases, providing recommendations and guidelines for future studies in this field. RESULTS AND CONCLUSIONS: Robust mechanistic evidence is available from in vitro studies and in vivo animal studies, usually employing cholecalciferol, calcidiol or calcitriol in pharmacologic rather than physiologic doses. Although many cross-sectional and prospective association studies in humans have shown that low 25-hydroxyvitamin D levels (i.e., <50 nmol/L) are consistently associated with chronic diseases, further strengthened by a dose-response relationship, several meta-analyses of clinical trials have shown contradictory results. Overall, large randomized controlled trials with sufficient doses of vitamin D are missing, and available small to moderate-size trials often included people with baseline levels of serum 25-hydroxyvitamin D levels >50 nmol/L, did not simultaneously assess multiple outcomes, and did not report overall safety (e.g., falls). Thus, no recommendations can be made to date for the use of vitamin D supplementation in general, parental compounds, or non-hypercalcemic vitamin D analogs in the prevention and treatment of extra-skeletal chronic diseases. Moreover, attainment of serum 25-hydroxyvitamin D levels well above the threshold desired for bone health cannot be recommended based on current evidence, since safety has yet to be confirmed. Finally, the promising findings from mechanistic studies, large cohort studies, and small clinical trials obtained for autoimmune diseases (including type 1 diabetes, multiple sclerosis, and systemic lupus erythematosus), cardiovascular disorders, and overall reduction in mortality require further confirmation.

24 Guideline Pharmacologic Therapy for Type 2 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes. 2017

Chamberlain, James J / Herman, William H / Leal, Sandra / Rhinehart, Andrew S / Shubrook, Jay H / Skolnik, Neil / Kalyani, Rita Rastogi. ·From St. Mark's Hospital and St. Mark's Diabetes Center, Salt Lake City, Utah; University of Michigan, Ann Arbor, Michigan; SinfoníaRx, Tucson, Arizona Glytec, Greenville, South Carolina; Touro University College of Osteopathic Medicine, Vallejo, California; Abington-Jefferson Health, Jenkintown, Pennsylvania; and Johns Hopkins University, Baltimore, Maryland. ·Ann Intern Med · Pubmed #28288484.

ABSTRACT: Description: The American Diabetes Association (ADA) annually updates the Standards of Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of patients with diabetes. Methods: For the 2017 Standards, the ADA Professional Practice Committee updated previous MEDLINE searches performed from 1 January 2016 to November 2016 to add, clarify, or revise recommendations based on new evidence. The committee rates the recommendations as A, B, or C, depending on the quality of evidence, or E for expert consensus or clinical experience. The Standards were reviewed and approved by the Executive Committee of the ADA Board of Directors, which includes health care professionals, scientists, and laypersons. Feedback from the larger clinical community informed revisions. Recommendations: This synopsis focuses on recommendations from the 2017 Standards about pharmacologic approaches to glycemic treatment of type 2 diabetes.

25 Guideline ABM Clinical Protocol #27: Breastfeeding an Infant or Young Child with Insulin-Dependent Diabetes. 2017

Miller, Diana / Mamilly, Leena / Fourtner, Shannon / Rosen-Carole, Casey. ·1 Pediatric Endocrinology, University at Buffalo , Buffalo, New York. · 2 Division of General Pediatrics, Maternal Fetal Medicine and General Pediatrics, University of Rochester , Rochester, New York. · 3 Division of Neonatology, Maternal Fetal Medicine and General Pediatrics, University of Rochester , Rochester, New York. ·Breastfeed Med · Pubmed #28135112.

ABSTRACT: A central goal of The Academy of Breastfeeding Medicine is the development of clinical protocols for managing common medical problems that may impact breastfeeding success. These protocols serve only as guidelines for the care of breastfeeding mothers and infants and do not delineate an exclusive course of treatment or serve as standards of medical care. Variations in treatment may be appropriate according to the needs of an individual patient.

Next